Medication Refractory Restless Legs Syndrome: Real-World Experience
Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…A case of Restless Abdominal Syndrome An Uncommon Variant of Restless Leg Syndrome
Objective: To identify restless abdominal syndrome as a potential cause of abdominal discomfort in patients presenting with discomfort in abdominal area which gets worse at…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…REM sleep behavior disorder in Parkinson´s Disease: a risk factor for Impulse Control Disorders.
Objective: We aimed to analyze de association between REM sleep behavior disorder (RBD) and impulse control disorders (ICD) in Parkinson´s disease (PD) patients and in…The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis
Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial
Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline
Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy
Objective: To report a patient with progressive supranuclear palsy (PSP) in whom an impulse control disorder (ICD) was triggered by a dopaminergic therapy. Background: ICDs…Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease
Objective: To assess the usage frequency of dopamine agonists (DA), the prevalence of impulse control disorder (ICD) in patients with Early-onset Parkinson’s Disease (EOPD), and…The role of depression in the development of Impulse Control Disorders in Parkinson´s Disease.
Objective: We aimed to investigate whether depression is associated with a higher risk of developing impulse control disorders (ICD) in Parkinson´s disease (PD) patients and…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 16
- Next Page »